A review of 69 clinical trials looked at how inhaled antibiotics affect people with cystic fibrosis, non-cystic fibrosis bronchiectasis, and ventilator-associated pneumonia. The study looked at several factors, including how well the medicine cleared germs, improved lung function, and reduced the frequency of flare-ups.
The results showed that inhaled antibiotics may improve lung function for those with cystic fibrosis. For people with non-cystic fibrosis bronchiectasis, the treatment was likely to reduce the frequency of flare-ups. The study also found that inhaled antibiotics may enhance or improve the clearing of germs and the clinical response in patients with cystic fibrosis and ventilator-associated pneumonia.
While the results show potential benefits for these conditions, the evidence is not consistent across all types of antibiotics or delivery methods. Some patients may experience side effects like bronchospasms. Because the evidence varies, these findings are not yet enough to change standard care for everyone. Patients should talk to their doctors about how these treatments might fit their specific needs.
